Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ALEC

ALEC - Alector Inc Stock Price, Fair Value and News

$1.90-0.05 (-2.56%)
Market Closed

23/100

ALEC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

23/100

ALEC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.55

Target 3M

$1.78

Target 6M

$1.65

ALEC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALEC Price Action

Last 7 days

-1.0%

Last 30 days

25%

Last 90 days

25%

Trailing 12 Months

11.8%

ALEC RSI Chart

ALEC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALEC Valuation

Market Cap

207.4M

Price/Earnings (Trailing)

-1.92

Price/Sales (Trailing)

3

Price/Free Cashflow

-1.05

ALEC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.55

Target 3M

$1.78

Target 6M

$1.65

ALEC Fundamentals

ALEC Revenue

Revenue (TTM)

69.0M

Rev. Growth (Yr)

-78.75%

Rev. Growth (Qtr)

-58.6%

ALEC Earnings

Earnings (TTM)

-107.7M

Earnings Growth (Yr)

17.89%

Earnings Growth (Qtr)

-13.57%

ALEC Profitability

Return on Equity

-186.68%

Return on Assets

-32.13%

Free Cashflow Yield

-95.27%

ALEC Investor Care

Shares Dilution (1Y)

11.46%

Diluted EPS (TTM)

-1.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202588.3M81.1M69.0M0
202496.4M55.3M61.5M100.6M
2023125.7M102.1M96.3M97.1M
2022227.4M300.7M133.2M133.6M
202118.0M21.4M197.9M207.1M
202022.8M19.0M22.2M21.1M
201928.4M28.2M24.4M21.2M
20188.4M15.2M21.6M27.7M
20171.2M2.1M2.9M3.7M
2016000416.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Alector Inc

ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEalector.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES239

Alector Inc Frequently Asked Questions

ALEC is the stock ticker symbol of Alector Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Alector Inc is 207.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ALEC's fair value in chart for subscribers.

The fair value guage provides a quick view whether ALEC is over valued or under valued. Whether Alector Inc is cheap or expensive depends on the assumptions which impact Alector Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALEC.

As of Wed Jan 28 2026, ALEC's PE ratio (Price to Earnings) is -1.92 and Price to Sales (PS) ratio is 3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALEC PE ratio will change depending on the future growth rate expectations of investors.